Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11780837 CXCR4 inhibitors and uses thereof

Patent 11780837 was granted and assigned to X4 Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
X4 Pharmaceuticals
X4 Pharmaceuticals
Date Filed
March 14, 2022
Date of Patent
October 10, 2023
Patent Applicant
X4 Pharmaceuticals
X4 Pharmaceuticals
Patent Application Number
17654722
Patent Citations
‌
US Patent 7354932 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
‌
US Patent 7354934 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
‌
US Patent 7390799 Apoptosis promoters
‌
US Patent 7452994 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
‌
US Patent 7491544 Chiral piperidine and quinucledine ligands
‌
US Patent 7501518 Methods of making 2,6-diaryl piperidine derivatives
‌
US Patent 7550484 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
‌
US Patent 7592351 Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds
‌
US Patent 7723525 Chemokine-binding heterocyclic compound salts, and methods of use thereof
‌
US Patent 7863293 CXCR4 chemokine receptor binding compounds
•••
Patent Inventor Names
Elyse Marie Josee Bourque
Renato Skerlj
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11780837
Patent Primary Examiner
‌
Joseph R Kosack

Find more entities like US Patent 11780837 CXCR4 inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo